The expression of an intestinal epithelial cell receptor is silenced in most human colorectal cancers that progress from benign to malignant, according to a Biology Letter in the 23 June 2005 issue of Nature (Vol. 435, No. 7045, pp. 1126-1130). In addition, Hans Clevers and colleagues report that loss of expression of this receptor, EphB2, accelerates the progression of colorectal cancer in mice.
This study contradicts previous work suggesting that EphB2 would be a good target in cancer therapy because of its overall upregulation in colorectal cancers compared with normal intestinal tissue. The authors note that this discrepancy underscores the need for careful study of potential drug targets.
Hans Clevers (Hubrecht Laboratory, Utrecht, The Netherlands)
(C) Nature press release.
Message posted by: Trevor M. D'Souza
Bookmark and Share this page (what is this?)
Social bookmarking allows users to save and categorise a personal collection of bookmarks and share them with others. This is different to using your own browser bookmarks which are available using the menus within your web browser.
Use the links below to share this article on the social bookmarking site of your choice.
Read more about social bookmarking at Wikipedia - Social Bookmarking
Variants Associated with Pediatric Allergic Disorder
Mutations in PHF6 Found in T-Cell Leukemia
Genetic Risk Variant for Urinary Bladder Cancer
Antibody Has Therapeutic Effect on Mice with ALS
Regulating P53 Activity in Cancer Cells
Anti-RNA Therapy Counters Breast Cancer Spread
Mitochondrial DNA Diversity
The Power of RNA Sequencing
‘Pro-Ageing' Therapy for Cancer?
Niche Genetics Influence Leukaemia
Molecular Biology: Clinical Promise for RNA Interference
Chemoprevention Cocktail for Colon Cancer
more news ...